Physician profile
Philippe E Prouet
NPI 1134562523
$5,841.59
in general payments reported to CMS, 2019-2025
50 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $385 · 2021: $472 · 2022: $523 · 2023: $1,194 · 2024: $1,599 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.21 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $714.71 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $592.95 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $533.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $481.66 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $350.41 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $321.71 | 2019-2025 | Enhertu, Injectafer |
| Gilead Sciences, INC. | $279.90 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $233.75 | 2020-2025 | |
| Emd Serono, INC. | $176.66 | 2020-2025 | |
| Janssen Biotech, INC. | $159.54 | 2020-2025 | Darzalex, Tecvayli, Erleada |
| Eusa Pharma (US) LLC | $134.12 | 2019-2020 | |
| Springworks Therapeutics, INC. | $113.20 | 2024-2025 | Ogsiveo |
| Astrazeneca Pharmaceuticals Lp | $111.13 | 2019-2025 | Imfinzi, Calquence |
| Eisai INC. | $91.76 | 2021-2025 | |
| Array Biopharma INC | $90.90 | 2020-2025 | Braftovi, Lorbrena, Mektovi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $89.76 | 2024-2025 | |
| Exelixis INC. | $85.27 | 2020-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $80.70 | 2023 | Imbruvica |
| Astellas Pharma US INC | $80.52 | 2019-2025 | Xtandi, Vyloy |
| Ipsen Biopharmaceuticals, INC | $76.53 | 2024-2025 | Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $75.88 | 2023-2025 | Fruzaqla, Alunbrig |
| Genentech USA, INC. | $72.15 | 2022-2025 | Venclexta, Tecentriq, Kadcyla |
| Beigene USA, INC. | $67.60 | 2020-2024 | Brukinsa |
| Blueprint Medicines Corporation | $61.68 | 2021-2022 | |
| Amgen INC. | $61.33 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $53.03 | 2021-2025 | |
| Sobi, INC | $52.56 | 2024-2025 | |
| Mirati Therapeutics, INC. | $50.92 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $45.56 | 2024-2025 | Zejula, Jemperli |
| Geron Corporation | $44.17 | 2025 | Rytelo |
| Epizyme, INC. | $42.51 | 2021 | |
| Puma Biotechnology, INC. | $32.63 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $30.73 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $29.92 | 2021 | |
| Kite Pharma, INC. | $28.31 | 2023 | Yescarta |
| Lilly USA, LLC | $28.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.22 | 2022 | |
| Incyte Corporation | $24.75 | 2019-2020 | |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Tg Therapeutics, INC. | $20.63 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.87 | 2024 | Monoferric |
| Rxsight INC | $17.22 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Alexion Pharmaceuticals, INC. | $17.22 | 2019 | |
| Progenics Pharmaceuticals, INC. | $16.81 | 2021 | |
| Clovis Oncology, INC. | $16.18 | 2019 | |
| Verastem, INC. | $15.63 | 2020 | |
| Morphosys, US INC. | $15.10 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.72 | 2024 | Givlaari |
| Stemline Therapeutics INC. | $13.51 | 2025 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Prouet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.